Perspectives

What can we say about the likely roles to be played by CAR- vs. TCR-modified cell therapies?

We explored the challenges of living with a rare disease and highlighted synergies across rare disease communities, as well as the implications for pharma.

Drs Crowley-Nowick and Keir set the stage for a successful launch as they consider the key components of a medical affairs team and their contributions on the road to launch and beyond.

Therapies designed to target cancers with specific molecular signatures have reshaped the landscape of oncologic drug development.1 As the next generation of tumour-agnostic therapies make their way through clinical trials, we should be asking ourselves what we can do to prepare for the upcoming challenge of reimbursement in this space, and what lessons can be learnt from the experience of existing therapies. Over the coming months, we will provide recommendations from our own experience and a review of the experiences of the tropomyosin receptor kinase (TRK) inhibitors larotrectinib and entrectinib to learn how to overcome the common challenges in this space. Here, in the second of our five-paper series, we focus on the difficulties of estimating the effectiveness of tumour-agnostic treatments in practice.